Practice Areas - Equity Capital Markets Law Firms and Lawyers
| Deal Date: | 06-07-2020 | Practice Area: | Equity Capital Markets |
| Deal Title: | SK Biopharmaceuticals KRX KOSPI Initial Public Offering | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
Simpson Thacher represented SK Biopharmaceuticals Co., Ltd., as issuer, and SK Holdings Co., Ltd., as selling shareholder, in connection with SK Biopharmaceuticals' initial public offering and listing on the KRX KOSPI Market, which included an international offering pursuant to Rule 144A and Regulation S.
The offering raised an aggregate of Won 959.3 billion (approximately USD800.1 million) for SK Biopharmaceuticals and SK Holdings, marking the largest initial public offering in Korea since 2017. Citigroup Global Markets Korea Securities Limited, NH Investment and Securities Co., Ltd., Morgan Stanley and Co. International PLC, Seoul Branch., Korea Investment and Securities Co., Ltd., SK Securities Co., Ltd., and Hana Financial Investment Co., Ltd. acted as underwriters for the offering.
|
||
| Financial Center: | Seoul | Value: | 500.01-1000.00 |
| Advised Party: | Issuer | Law Firm | Simpson Thacher |
| Issuer Jurisdiction- | Republic of Korea | Listing Jurisdiction- | Republic of Korea |
| Classification: |
Initial Public Offerings Korea Exchange: KRX KOSPI |
Lawyer | Jin Hyuk Park |
